Key facts
- It has raised $425K across 2 recorded rounds; the latest was Seed Round ($425K) in Nov 2025.
- 3 institutional filers report fund marks on NeuroGeneces across 8 filings.
- NeuroGeneces has filed 4 Form Ds with the SEC since 2017, most recently May 2026 ($425K sold to 13 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for NeuroGeneces
Create free account
No card required
Funding rounds
2 roundsDec 2021Accelerator/Incubator—▮
About NeuroGeneces
- Industry
- Other Healthcare Technology Systems
PA Mark — not yet priced
NeuroGeneces doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in NeuroGeneces shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
3 filers · latest May 20263 SEC-registered funds reported 8 fair-value marks on NeuroGeneces between Apr 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.